Business Context and Reporting Period
Dianthus Therapeutics, Inc. (DNTH) filed a Form 8-K on March 10, 2026, reporting the entry into a material definitive agreement. The Company, incorporated in Delaware and listed on The Nasdaq Capital Market, announced a public offering of common stock and pre-funded warrants.
Key Financial Metrics
- Offering Size: 7,313,582 shares of common stock and 402,468 pre-funded warrants.
- Offering Price: $81.00 per share for common stock; $80.999 per warrant.
- Over-Allotment Option: Underwriters exercised their option in full on March 11, 2026, to purchase an additional 1,157,407 shares.
- Net Proceeds: Approximately $673.5 million (after underwriting discounts, commissions, and estimated expenses).
- Closing Date: Expected March 12, 2026.
Material Changes
This filing represents a significant capital raise event. The Company secured approximately $673.5 million in net proceeds through the sale of equity and pre-funded warrants. The full exercise of the 30-day over-allotment option by underwriters indicates strong initial demand for the offering.
Guidance, Outlook, and Risks
The filing does not provide specific operational guidance, revenue forecasts, or management commentary regarding future clinical milestones. The primary risk disclosed relates to the indemnification agreement, where the Company agreed to indemnify underwriters against certain liabilities under the Securities Act. The pre-funded warrants include beneficial ownership limitations (4.99%, 9.99%, or 19.99%) which may be adjusted with 61 days' prior notice.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on March 12, 2026.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Review the use of proceeds disclosed in the final prospectus supplement (File No. 333-293014).
- Monitor for any subsequent filings regarding the exercise of pre-funded warrants.